These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 28646565)

  • 1. Complete molecular remission in relapsed and refractory acute myeloid leukaemia with MLL-AF9 treated with chidamide-based chemotherapy.
    Lun Y; Yang JJ; Wu Y
    J Clin Pharm Ther; 2017 Dec; 42(6):786-789. PubMed ID: 28646565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
    Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
    Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study.
    Wang L; Luo J; Chen G; Fang M; Wei X; Li Y; Liu Z; Zhang Y; Gao S; Shen J; Wang X; Gao X; Zhou W; Ma Y; Liu H; Li X; Yang L; Sun K; Yu L
    Clin Epigenetics; 2020 Sep; 12(1):132. PubMed ID: 32873343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognostic significance of detecting MLL-AF9 fusion gene expression in patients with acute myeloid leukemia by real-time fluorescence quantitative PCR].
    Huang S; Yang H; Gao L; Dou LP; Xu YY; Wang N; Wang LL; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1435-40. PubMed ID: 24370025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
    Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
    Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway.
    Wang H; Liu YC; Zhu CY; Yan F; Wang MZ; Chen XS; Wang XK; Pang BX; Li YH; Liu DH; Gao CJ; Liu SJ; Dou LP
    J Exp Clin Cancer Res; 2020 Dec; 39(1):278. PubMed ID: 33298132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
    Li Y; Wang Y; Zhou Y; Li J; Chen K; Zhang L; Deng M; Deng S; Li P; Xu B
    Clin Epigenetics; 2017; 9():83. PubMed ID: 28814980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
    Shi Y; Dong M; Hong X; Zhang W; Feng J; Zhu J; Yu L; Ke X; Huang H; Shen Z; Fan Y; Li W; Zhao X; Qi J; Huang H; Zhou D; Ning Z; Lu X
    Ann Oncol; 2015 Aug; 26(8):1766-71. PubMed ID: 26105599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.
    Shi Y; Jia B; Xu W; Li W; Liu T; Liu P; Zhao W; Zhang H; Sun X; Yang H; Zhang X; Jin J; Jin Z; Li Z; Qiu L; Dong M; Huang X; Luo Y; Wang X; Wang X; Wu J; Xu J; Yi P; Zhou J; He H; Liu L; Shen J; Tang X; Wang J; Yang J; Zeng Q; Zhang Z; Cai Z; Chen X; Ding K; Hou M; Huang H; Li X; Liang R; Liu Q; Song Y; Su H; Gao Y; Liu L; Luo J; Su L; Sun Z; Tan H; Wang H; Wang J; Wang S; Zhang H; Zhang X; Zhou D; Bai O; Wu G; Zhang L; Zhang Y
    J Hematol Oncol; 2017 Mar; 10(1):69. PubMed ID: 28298231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel AF9 breakpoint in MLL-AF9-positive acute monoblastic leukemia.
    Alonso CN; Longo PL; Gallego MS; Medina A; Felice MS
    Pediatr Blood Cancer; 2008 Apr; 50(4):869-71. PubMed ID: 18000862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel RT-qPCR assay for quantification of the MLL-MLLT3 fusion transcript in acute myeloid leukaemia.
    Abildgaard L; Ommen HB; Lausen B; Hasle H; Nyvold CG
    Eur J Haematol; 2013 Nov; 91(5):394-8. PubMed ID: 23772754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic effects of the KDM4C inhibitor SD70 and the menin inhibitor MI-503 against MLL::AF9-driven acute myeloid leukaemia.
    Zhu W; Ding Y; Huang W; Guo N; Ren Q; Wang N; Ma X
    Br J Haematol; 2024 Aug; 205(2):568-579. PubMed ID: 38877874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of loss of BH3-only proteins on the development and treatment of MLL-fusion gene-driven AML in mice.
    Bilardi RA; Anstee NS; Glaser SP; Robati M; Vandenberg CJ; Cory S
    Cell Death Dis; 2016 Sep; 7(9):e2351. PubMed ID: 27584789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term remission of therapy-related acute myeloid leukemia with a new t(11;18)(q23;q21.2) translocation and KMT2A-ME2 (MLL-ME2) fusion gene.
    Szotkowski T; Jarošová M; Zimmermannová O; Meyer C; Marschalek R; Zuna J; Hubáček J; Indrák K
    Cancer Genet; 2015 Dec; 208(12):610-4. PubMed ID: 26556690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete molecular remission in refractory acute myeloid leukemia with MLL/AF9 treated with gemtuzumab ozogamicin.
    Asano H; Yamamoto G; Hosoi M; Takahashi T; Hangaishi A; Kurokawa M
    Leuk Res; 2010 Jul; 34(7):e152-3. PubMed ID: 20061019
    [No Abstract]   [Full Text] [Related]  

  • 16. MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia.
    Prange KHM; Mandoli A; Kuznetsova T; Wang SY; Sotoca AM; Marneth AE; van der Reijden BA; Stunnenberg HG; Martens JHA
    Oncogene; 2017 Jun; 36(23):3346-3356. PubMed ID: 28114278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of MLL::AF9 Gene Rearrangement on Survival of Acute Myeloid Leukaemia Patients: An Insight into Pakistani Population.
    Tariq M; Shahab S; Saeed JR; Hussain Z; Zaidi U; Farzana T; Ahmad S
    J Coll Physicians Surg Pak; 2024 Apr; 34(4):424-428. PubMed ID: 38576284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of relapsed acute myelogeneous leukaemia with MLL/AF 6 fusion after stem cell transplantation by intensive reinduction followed by adoptive immunotherapy.
    Schuster FR; Führer M; Woessmann W; Reiter A; Harbott J; Viehmann S; Borkhardt A
    Leukemia; 2005 Jul; 19(7):1273-4; author reply 1275-6. PubMed ID: 15902291
    [No Abstract]   [Full Text] [Related]  

  • 19. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.
    Stubbs MC; Kim YM; Krivtsov AV; Wright RD; Feng Z; Agarwal J; Kung AL; Armstrong SA
    Leukemia; 2008 Jan; 22(1):66-77. PubMed ID: 17851551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transformation from acute promyelocytic leukemia in pregnancy to acute myeloid leukemia with MLL-AF9 fusion gene: A case report and literature review.
    Gao Y; Han N; Jiang Y; Lu Z
    Medicine (Baltimore); 2023 Dec; 102(48):e36403. PubMed ID: 38050244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.